Keyword: Japan

Hoping to expand its hospital portfolio in Japan, the Novartis generics unit is buying Aspen Pharmacare's operations there for up to €400 million.

Daiichi Sankyo is pulling out of its Movantik co-marketing deal with AstraZeneca and cutting loose two Inspirion opioid painkillers.

FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.

Sanofi has been paring away jobs on both sides of the Atlantic for years. Now, it's offering voluntary early retirements to employees in Japan.

Pfizer's mature drugs plunged in China. AZ and GSK race their oral anemia drugs to Asia. Biotech leaders worry IP crackdown will hurt collaboration.

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Roche, Daiichi and AZ nab global first nods from Japan; Celgene hands back PD-1 to BeiGene; China offers incentive to generic makers.

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Roche has its first global approval for Rozlytrek, a drug that targets NTRK fusion-positive tumors and one that will challenge Bayer's Vitrakvi.

GSK's Shingrix nabs Chinese nod; Roche's Chugai invests $1.15 billion in new R&D site; Japanese authority warns of Verzenio's side effect.